Ongoing Risk Monitoring
Arcova turns biotech risk and complexity into clear decision-making, while keeping all your diligence and technical risk management in one place.
Not sure if you need ongoing risk monitoring? Book a demo and we'll show you how Arcova can help.
Cortexa
Applies deep learning to uncover mechanistic insights and novel targets in Alzheimer's and related neurodegenerative diseases
Leadership & Team
IP & Legal
Clinical & Regulatory
Overview
Cortexa is progressing on lead selection and preclinical studies, but the CSO's departure leaves a critical AI/ML leadership gap. Core IP is intact, though model inconsistencies and a patent challenge add pressure.
Next Decision
Request an update on AI leadership plans and model refinement before Q3 R&D planning. Clarity is needed on whether the team can sustain platform progress without a new CSO.
Contingency
If gaps persist into Q3, consider tying follow-on investment to resolving validation issues and securing senior technical leadership.
Key Risk Alerts
| Category | Status | Risk Level | Explanation | Trend |
|---|---|---|---|---|
Science | Medium | 6.5/10 | Lead compound stability issues being addressed | |
Team | High | 8/10 | CSO departure creates critical knowledge gap | |
IP | Low | 2/10 | Strong patent portfolio with minimal challenges | |
Regulatory | Medium | 5.5/10 | Pre-IND feedback requires additional studies | |
Funding | Low | 3/10 | Recent Seed round provides 14-month runway | |
Competition | Medium | 7/10 | New competitor entered Phase 1 with similar MOA |
Publications by Quarter
Recent Activity
Novel AI approach for neurological drug target identification
AI-Driven Drug Discovery Platform Presentation
Best AI Innovation in Drug Discovery
Cortexa's AI platform shows 3x improvement in target identification
AI Platform Validation
Jan 2025Completed
Demonstrated 3x improvement in target identification accuracy
Lead Compound Selection
May 2025In Progress
ML models predicting 3 promising candidates for synthesis
Preclinical Studies
Jul 2025In Progress
In vitro validation of top candidates ongoing
IND-Enabling Studies
Dec 2025Planned
Planning phase for regulatory requirements